

**PRESS RELEASE**



**GlycoVaxyn to Present at the Sofinnova Japan Biopharma Partnering Conference**

**SCHLIEREN, Switzerland, October 3, 2011** – GlycoVaxyn today announced that Philippe Dro, chief executive officer, will present at the [Sofinnova Japan Biopharma Partnering Conference](#) at 12:10 p.m. JST, October 4 at the Conrad Hotel in Tokyo. Mr. Dro will discuss GlycoVaxyn's bio-conjugate bacterial vaccine technology and the Company's product development programs.

**About GlycoVaxyn**

GlycoVaxyn is developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, proprietary *in vivo* glycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a simplified biological process that circumvents many of the challenges and uncertainties involved in currently used methods. In addition to the clinical stage *Shigella* vaccine, lead programs in preclinical stage are aimed at the prevention of hospital acquired *Staphylococcus aureus* infections, as well as pneumococcal invasive diseases and meningococcal group B meningitis. For further information, visit [www.glycovaxyn.com](http://www.glycovaxyn.com).

**Contacts:**

Philippe Dro  
GlycoVaxyn AG  
Tel: +41 44 733 8581  
[philippe.dro@glycovaxyn.com](mailto:philippe.dro@glycovaxyn.com)

Robert Flamm  
Russo Partners, LLC  
Tel: +212-845-4226  
[robert.flamm@russopartnersllc.com](mailto:robert.flamm@russopartnersllc.com)